Deletion of chromosome 20q (del(20q)) is a common chromosomal abnormality associated with myeloid neoplasms including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome, myelodysplastic syndrome/MPN overlap disorders and acute myeloid leukemia. 1, 2 The del(20q) lesion is present in patients with myelofibrosis (MF) at a high frequency (23%) and is thus considered to be one of the most frequent cytogenetic abnormalities in MF. 3 However, the identity of the target tumor suppressor gene(s) within 20q involved in the pathogenesis of MF and other myeloid neoplasms remains elusive.
The PTPN1 gene encoding protein tyrosine phosphatase nonreceptor type 1 (PTPN1; also known as PTP1B) is located on human chromosome 20q13.1-q13.2. Both oncogenic and tumor suppressor functions for PTPN1 have been suggested. PTPN1 is overexpressed in breast cancer and deletion of Ptpn1 inhibits ErbB2-Accepted article preview online 23 January 2017; advance online publication, 14 February 2017 induced breast tumorigenesis in mice. 4 Somatic loss-of-function mutations in PTPN1 have been associated with mediastinal B-cell lymphoma and Hodgkin lymphoma. 5 Moreover, ablation of Ptpn1 accelerates B-cell lymphomagenesis and decreases survival in p53-null mice.
6 PTPN1 can negatively regulate Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling, 7 which is frequently found to be activated in MPNs. 8 The common occurrence of del(20q) involving the PTPN1 locus in MPN and the negative regulatory role of the corresponding phosphatase in JAK/ STAT signaling led us to hypothesize that PTPN1 is a potential tumor suppressor gene within 20q involved in MPN.
Using cytogenetic and single-nucleotide polymorphism arraybased karyotyping, we detected the presence of 20q deletion and assessed the status of the PTPN1 gene locus in a cohort of 916 patients with myeloid malignancies (Supplementary Tables 1 and  2 ). The del(20q) involving PTPN1 deletion was identified in 11/135 cases (8%) of secondary acute myeloid leukemia, 1/120 cases (1%) of primary acute myeloid leukemia, 25/147 cases (17%) of MPN, 6/135 cases (4%) of myelodysplastic syndrome/MPN overlap disorders and 47/379 cases (12%) of myelodysplastic syndrome (Supplementary Figure 1) . Thus, del(20q) involving PTPN1 deletion was more commonly found in MPN in comparison with other myeloid neoplasms. We also determined that 22% of MF patients (25/116 cases) in our cohort had del(20q) with PTPN1 deletion and 53% of MF patients (62/116 cases) were positive for the JAK2V617F mutation, 10% (12/116 cases) were positive for CALR mutation and 7% (8/116 cases) were positive for MPL mutation (Figure 1a ). Among the 25 MF patients who had del(20q) with PTPN1 deletion, 17 were also positive for the JAK2V617F mutation, 2 patients were positive for CALR mutation, whereas 6 other del(20q) patients did not have any of the known MPN-associated mutations (Supplementary Figure 2) . Interestingly, six cases with various myeloid neoplasms had somatic microdeletion of the PTPN1 locus (data not shown), but none of these cases had MF and coexisting MPN driver mutations. Fluorescence in situ hybridization using a PTPN1-specific probe confirmed the presence of monoallelic deletion of PTPN1 in MPN/MF bone marrow (BM) cells (Supplementary Figure 3) . Overall, these data suggest that PTPN1 deletion occurs in myeloid malignancies and is more frequently present in MPN/MF.
To test the effects of Ptpn1 deletion on hematopoiesis, we crossed Ptpn1-floxed (Ptpn1fl/fl) mice 9 with Mx1-Cre mice. 10 At 4 weeks after birth, control (Ptpn1fl/fl; no Cre) and Mx1-Cre; Ptpn1fl/fl (referred as Ptpn1 cKO ) mice were injected with three doses of 2 μg polyinosine-polycytosine (pI-pC) to induce Ptpn1 deletion in the mice hematopoietic compartments. As shown in . Hematopoietic progenitor colony assays showed significant increases in colony-forming unit-granulocyte and monocyte colonies in the BM and spleens of Ptpn1 cKO mice compared with control animals (Figure 1i ). We also observed significantly increased numbers of colony-forming unit-megakaryocytic colonies in the BM of Ptpn1 cKO mice (Figure 1j ). Taken together, these data suggest that loss of Ptpn1 promotes the expansion of HSC and increases myeloid/megakaryocytic differentiation.
Histopathologic analyses of the BM sections from Ptpn1 cKO mice showed increased granulocytic precursors with decreased erythroid precursors and mildly increased megakaryocytes (Figure 1k ). Spleen sections from Ptpn1 cKO mice exhibited high myeloid to erythroid ratios and increased megakaryocytes. Reticulin staining demonstrated fibrosis (grade 2) in the BM and spleens of Ptpn1 cKO mice at 52 weeks after pI-pC induction, whereas control animals did not exhibit fibrosis at that age (Figure 1k ). Taken together, these results suggest that deletion of Ptpn1 induces an MPN-like phenotype, which progresses to MF over time. cKO mice showed increased myeloid to erythroid ratios and mild increase in megakaryocytes. Spleens of Ptpn1 cKO mice showed extramedullary hematopoiesis, with a high myeloid to erythroid ratios and increase in both granulocytic and megakaryocytic cells. Reticulin staining showed fibrosis (grade 2 of 3) in the BM and spleens of Ptpn1 cKO mice at 52 weeks after Ptpn1 deletion. Scale bars, 20 μm.
To determine whether the MPN/MF-like phenotype observed in Ptpn1 cKO mice was cell intrinsic, we transplanted BM cells from control and Ptpn1 cKO mice into lethally irradiated C57BL/6 wild-type recipient mice as outlined in Figure 2a . Compared with recipients of control BM (bone marrow transplantation (BMT)-Control), transplanted animals receiving Ptpn1 cKO mice BM (BMTPtpn1 cKO ) exhibited significantly increased white blood cell and neutrophil counts in their peripheral blood (Figures 2b and c) . Histologic analysis confirmed the development of fibrosis in the BM and spleens of BMT-Ptpn1 cKO mice at 18 weeks after transplantation (Figure 2d) . These results suggest that the observed effect of Ptpn1 deletion in the development of MPN/ MF was cell intrinsic.
To evaluate the effects of Ptpn1 deletion in hematopoietic stem cell reconstitution, we performed competitive repopulation assays as outlined in Figure 2e . The frequency and total number of donor-derived (CD45. Figure 6b and Figure 2g ). Taken together, these results suggest that loss of Ptpn1 increases the repopulating capacity of HSC and promotes expansion of myeloid lineage cells.
To investigate the effects of Ptpn1 deletion on hematopoietic signaling, we performed immunoblot analysis on total BM cell extracts from control and PTPN1 cKO mice. We observed markedly increased phosphorylation of STAT5, AKT and ERK in PTPN1 cKO BM compared with control BM cells (Figure 2h ). We also observed enhanced phosphorylation of STAT5, AKT and ERK upon PTPN1 knockdown in human peripheral blood mononuclear cells as well as in murine hematopoietic Ba/F3 cells ( Supplementary Figures 7  and 8a ). In addition, PTPN1 knockdown significantly increased proliferation in Ba/F3 cells (Supplementary Figure 8b) . Constitutive phosphorylation of JAK2/STAT5, AKT and ERK has been frequently observed in MPN/MF. 8 Moreover, STAT5, AKT and/or ERK signaling pathways have been shown to have important roles in the pathogenesis of MPN/MF. [11] [12] [13] Therefore, it is plausible that enhanced phosphorylation/activation of STAT5, AKT and ERK caused by Ptpn1 deletion is likely to contribute to the development of MPN/MF-like phenotype in Ptpn1 cKO mice. Consistent with previous reports suggesting that only heterozygous deletions of 20q are associated with myeloid malignancies, 1,2,14 we observed monoallelic deletion of PTPN1 in MPN/MF. Monoallelic deletion does not always correspond to 50% expression of the gene, as has been shown for other 20q target genes, L3MBTL1, SGK2 and MYBL2, where heterozygous deletion results in almost complete loss or~80% reduction in expression of these genes in patients. 14, 15 We identified monoallelic PTPN1 deletion in MPN patient-derived UKE-1 cell line carrying del(20q) (Supplementary Figure 9a) . We observed more than 90% reduction in PTPN1 protein expression in UKE-1 cell line compared with MPN patient-derived SET-2 cell line expressing wild-type PTPN1 (Supplementary Figures 9a and b) . Mechanisms involving aberrant methylation and/or elevated expression of microRNAs have been suggested to cause further reduction in expression of tumor suppressor genes. 14, 15 Future studies will determine if any such mechanisms exist in the regulation of PTPN1 expression in patients with MPN/MF. In summary, our data suggest a tumor suppressor role for PTPN1 in MPN/MF. However, we cannot exclude the existence of additional target genes in 20q involved in the pathogenesis of MPN/MF. It remains possible that haploinsufficiency of other target genes within 20q or additional genetic lesions outside of 20q may cooperate with PTPN1 deletion in the pathogenesis of MPN/MF. We observed coexistence of PTPN1 deletion and JAK2V617F mutation in significant cases of MF. Our preliminary data show that heterozygous or homozygous deletion of PTPN1 increases the severity of MPN in Jak2V617F-knock-in mice. Future studies will determine whether loss of PTPN1 cooperates with the JAK2V617F mutation in the pathogenesis of MPN. (Control, n = 4; Ptpn1 cKO , n = 4). Student's t-test was used to compare between two groups of mice (*Po 0.05; **P o0.005). (h) Total BM cell extracts from primary control and Ptpn1 cKO mice were immunoblotted with phospho-specific or total antibodies against STAT5, AKT and ERK. β-Actin was used as a loading control. Representative blots from four independent experiments are shown.
